|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Studies have demonstrated that pancreatic cancer is associated with various genetic abnormalities in oncogenes and tumor suppressor genes including p53.
|
10680837 |
2000 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In addition, it seems that cooperation of Ki-ras PM and p53 expression may predict a poor prognosis in Chinese patients with pancreatic cancer.
|
10750666 |
2000 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Frequent P53 mutations and Ki-ras codon 12 point mutations have been reported in pancreatic cancer.
|
10950039 |
2000 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In this study we evaluated whether the mutation rate of the TP53 and p16INK4a genes of pancreatic cancers differs in pancreatic cancer patients with and without multiple primaries.
|
11075991 |
2000 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
|
11097231 |
2000 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results show that transfer of wild-type p53 and p16 produces significant growth suppression of pancreatic cancer in vitro and in vivo.
|
11313791 |
2001 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer.
|
11332152 |
2001 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The mutation profiles of p53 and K-ras genes in pancreatic cancer resemble that in bladder cancer rather than that in lung cancer.
|
11561602 |
2002 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is particularly resistant to apoptosis by antineoplastic agents, which is partly attributable to the lack of functional p53.
|
11585734 |
2001 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2.
|
11694525 |
2002 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that overexpression of p21(WAF1/CIP1) occurs early in the development of PanIN, before aberrations in p53, cyclin D1, and DPC4/Smad4 expression. p21(WAF1/CIP1) overexpression, independent of p53 and/or DPC4/Smad4 expression, may reflect increased Ras activity, either directly through activating K-ras mutations or as a consequence of HER-2/neu (ERBB2) overexpression, both of which are common in PC and in early events in the development of PanIN.
|
11751405 |
2001 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Activation of the proto-oncogene K-Ras and inactivation of the tumour suppressor gene loci INK4a, p53 and SMAD4 are characteristic for pancreatic cancer.
|
12079267 |
2002 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
|
12171884 |
2002 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
We investigated the p53 status in core exon-4 to -9 (codon 33-331) by direct DNA sequencing in a series of 72 pancreatic cancers and analyzed the effects of p53 abnormalities on the patients' survival and the efficacy of adjuvant chemotherapy.
|
12561067 |
2003 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Detection of K-ras mutation combined with p53 mutation in stool can aid in the screening of pancreatic cancer.
|
12609076 |
2002 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
There is increasing knowledge about the genetic basis of pancreatic cancer (PaCa).Tumor suppressor genes (TSGs; e.g. p53 and DPC4) and oncogenes (e.g.
|
12748427 |
2003 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
p14ARF upregulation of p53 and enhanced effects of 5-fluorouracil in pancreatic cancer.
|
12935400 |
2003 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Trp53(+/-) mice overexpressing Tgfalpha in a pancreas-specific manner represent a well-established animal model for pancreatic cancer.
|
14506698 |
2003 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Using the whole-cell recording mode of the patch-clamp technique, functional ion channels were electrophysiologically characterized in PANC-1 (K-ras G12D (+/-), p53 R273C, Deltap16), BxPC-3 (smad4-, p53 Y220C, Deltap16), and MiaPaCa-2 [transforming growth factor-beta receptor type II defect, K-ras G12C(-/-), p53 R248W, Deltap16] human pancreatic cancer cell lines.
|
14978241 |
2004 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results strongly suggest that AxdAdB-3 possesses a wider therapeutic potential than previously believed, given that most pancreatic cancers have abnormalities in both the TP53 and RB pathways.
|
15084981 |
2004 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
In this study we examine whether combining Ad-mediated delivery of p53 or p16(INK4A) with clinically relevant chemotherapeutic drugs has therapeutic potential for pancreatic cancer.
|
15133762 |
2004 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuated form, both due to the APC germline mutation; the Lynch syndrome due to mutations in mismatch repair genes, the most common of which were found to be MSH2, MLH1, and MSH6 germline mutations; the hereditary breast-ovarian cancer syndrome with BRCA1 and BRCA2 germline mutations; the Li-Fraumeni (SBLA) syndrome due to the p53 mutation; and the familial atypical multiple mole melanoma in association with pancreatic cancer due to the CDKN2A (p16) germline mutation.
|
15264268 |
2004 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This study was focused on the mutations of p53 and DPC4 detectable in the bile of patients with histologically proven pancreatic cancers.
|
15565642 |
2004 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In an initial survey of KRAS2, TP53 and DPC4 genetic status in lethal metastatic pancreatic cancers, activating KRAS2 mutations were detected in 82% of cases and inactivating TP53 mutations in 55% of cases, consistent with rates of genetic alteration of these genes in early stage pancreatic cancers.
|
15846069 |
2005 |
|
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
|
16127777 |
2005 |